## UW Department of Pharmacy Faculty Meeting Agenda
**Monday, May 18th - 09:00 to 11:00 am**
**Venue:** Zoom  
**Conference URL:** https://washington.zoom.us/j/860946066  
**Zoom Phone Number:** +1 197 247 1195  
**Meeting ID:** 860 946 066

<table>
<thead>
<tr>
<th>Topic/ Business</th>
<th>Presenter</th>
<th>Appro. time</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Welcome and Announcements</td>
<td>White</td>
<td>20 min</td>
<td></td>
</tr>
<tr>
<td>• Hazlet Retirement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Merit review update</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Approval of Minutes (March 2020 meeting) [Vote requested]</td>
<td>White</td>
<td>2 min</td>
<td></td>
</tr>
<tr>
<td>3. Space Committee Update</td>
<td>Stergachis</td>
<td>5 min</td>
<td></td>
</tr>
<tr>
<td>4. BRAMS Faculty Appointment [Vote Requested]</td>
<td>Stergachis</td>
<td>5 min</td>
<td></td>
</tr>
<tr>
<td>• Affiliate Assistant Professor: Maria Agapova</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. CHOICE Updates and Appointment [Vote Requested]</td>
<td>Basu</td>
<td>15 min</td>
<td></td>
</tr>
<tr>
<td>• Proposed Graduate Program Name Change: Health Economics and Outcomes Research</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Affiliate Assistant Professor Appointment: Josh Roth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="https://uw.kuali.co/cm/#/courses/view/5ebd71980e813b2600c87749">https://uw.kuali.co/cm/#/courses/view/5ebd71980e813b2600c87749</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. EE Update</td>
<td>Danielson</td>
<td>20 min</td>
<td></td>
</tr>
<tr>
<td>8. Work Group on Curriculum Threads Discussion</td>
<td>Marcum Mike</td>
<td>20 min</td>
<td></td>
</tr>
<tr>
<td>9. 5 and 10 Presentation</td>
<td>Werth</td>
<td>10 min</td>
<td></td>
</tr>
<tr>
<td>10. Other Business</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Welcome/ Acknowledgements/ Announcements

### Discussion:

**Welcome and Announcements (White):**
Steve White welcomes everyone to the second remote faculty meeting and thanks all of the faculty for their extensive and impressive conversion from in-person to on-line teaching. Acknowledging the impressive work being conducted by the faculty with regard to remote teaching. Steve shares that the Provost has sent out a note regarding mid-course evaluations. This is an opportunity to gather input and insight from the students, seeing how they are doing and how we can assist in their learning. Steve invites the faculty to contact Patricia Hedtke early this week if this is something they would like to do for their course.

Andy Stergachis shared a brief update from the Space Committee. Andy notes that the committee has met 5 times, and has toured the new F wing space. Progress on space allocation is proceeding steadily, however the original aggressive timeline has slowed. Andy acknowledges the committee’s diligent work, particularly in ensuring realistic cost estimates with the proposal to the Dean. Renovating the new space will come with a substantial price tag, and in order to make accurate recommendations the committee has engaged Facilities Capital Projects team.

## Approval of Minutes

### Discussion

The DRAFT Meeting Minutes of the March 2020 faculty meeting were presented to all prior to the meeting for review.

### Motion to Approve:

First: Don Downing  
Second: Karan Dawson

### Vote

**Eligible:** 38  
**Yes:** 35  
**No:** 0  
**Abstain:** 0  
**Absent for Vote:** 3

Note: Votes included from those present at the meeting and via email response.
## 3. Curriculum Updates

<table>
<thead>
<tr>
<th>15 min</th>
<th>Open Discussion/Chan</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gold and Purple Curriculum:</strong></td>
<td></td>
</tr>
<tr>
<td>Steve shares updates from the Curriculum Committee on behalf of Lingtak Chan. The committee has been routinely meeting with student representatives who convey that the students are highly appreciative of the faculty’s efforts, and offer a few suggestions. The first recommendation discusses the number of emails currently in circulation, and shares that the current number is overwhelming. the students would prefer one email per week if possible, to minimize confusion and ease stress. Additionally, students recommend adding course zoom links to the front page of the syllabus, stating this will help with locating the link before each class period.</td>
<td></td>
</tr>
<tr>
<td>A request has been made for non-registered students to gain access to recordings for some elective courses. Peggy Odegard shares that this topic has been discussed by the Executive Committee, and while the decision remains at the descention of the course faculty, this can be a slippery slope that could evolve into a very large request. Peggy recommends holding off on making a definitive recommendation at the current time, but believes this would be worth reconsidering once things calm down. There is potential in developing a continuing education mechanism. Mary Hebert suggests that developing such a mechanism could provide a source of revenue for the school and department.</td>
<td></td>
</tr>
</tbody>
</table>

## 4. Experiential Education/Advising and Student Success

<table>
<thead>
<tr>
<th>30 min</th>
<th>Danielson/Chang/Allen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jennifer Danielson provides an update from the Experiential Education team. There are a number of students who are displaced, she shares, and the EE team is working to find placement as quickly as possible. Jen acknowledges and thanks the faculty members who have created alternative experiences for these students. The APPE team is working hard to finalize placement of students for next year, but Jen recognizes that this has been a challenge due to COVID19’s impact. This situation continues to evolve.</td>
<td></td>
</tr>
<tr>
<td>Jennifer Chang presents current trends in Preceptor Development, and provides an update regarding the Certificate of Merit in Precepting. Jennifer acknowledges the department’s faculty who have received this certificate this year, and thanks everyone for all their hard work. Current trends in preceptor development indicate an increase in the number of preceptors receiving merit since 2017, with fewer requiring follow up each year. Jennifer recommends continuing the current development process, with the goal of continuing this trend moving forward.</td>
<td></td>
</tr>
</tbody>
</table>
| Rachel Allen provides an update regarding WIP site recruitment. WIP will begin off site work beginning next year, and most sites have indicated they are most interested in hosting students from January through June. The WIP team has adjusted to this model to accommodate this request, and is taking the opportunity to orient students to ambulatory care. Regarding recruitment, Rachel shares that site recruitment has gone on hold for March and April in an effort to be respectful to sites needing to focus on patient care. The team looks forward to recruitment picking back up in the near future. The goal is to wrap up this process in May, and
Rachel shares that while there certainly are challenges, the team is in very good shape.

Steve White thanks Jen and her team for all their efforts.

<table>
<thead>
<tr>
<th>5. 5 and 10 Presentation</th>
<th>Marcum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion</td>
<td>Jenny Bacci presented her research on Community Pharmacy Transformation.</td>
</tr>
</tbody>
</table>

Meeting is Adjourned.
May 19, 2020

Sean Sullivan, PhD
Dean and Professor
School of Pharmacy
University of Washington, Seattle

Dear Dean Sullivan:

We would like to request a change in the title of the graduate degree program in the Department of Pharmacy, which is overseen by the core faculty in the CHOICE Institute. As you know, we advertise our program as a Masters or a PhD program in *Pharmaceutical Outcomes Research and Policy*. However, students obtain a graduate degree certificate stating that their degree is in *Pharmaceutical Sciences*. This is the same degree title that is conferred to graduate students in the other departments of SOP. The difference is that unlike these other students, other students are not trained in basic science research, but rather in population health and social sciences. It has become increasingly clear to us, and as conveyed by many of our alumni and current students, that signaling the right degree title is crucial in an ever-increasing competitive marketplace.

We would like to request the title of *Health Economics and Outcomes Research (HEOR)* as the new name of our graduate degree programs. There are many reasons to choose this title. First, during the creation of the CHOICE Institute, we made a strategic decision to promote the recognition of PORPP and become an international hub of excellence in the broader areas of health outcomes research, pharmacoepidemiology, health economics, and policy. HEOR, now an established and an internationally-recognized field best captures the type of research we do and the training that we impart to our students. Second, the field of HEOR has grown exponentially in the last 25 years as governments and other payers grapple with how to provide the best possible health outcomes at affordable costs. The International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) mission is to promote HEOR excellence to improve decision making for health globally. Current and past members of the CHOICE Institute have contributed to the creation and development
of this Society that now spans more than 20,000 individual and chapter members from 110+ countries worldwide. Four of the last six Presidents of the Society have direct connections to our program. The missions of our graduate program, and the CHOICE Institute, squarely align with the mission of the Society, and also the goals of the HEOR field.

Third, the CHOICE faculty formally sought and received approval to change the prefix for all core course offerings from one that reflected the Department of Pharmacy (PHARM) to one that reflects the discipline of Health Economics and Outcomes Research (HEOR). This change was approved by the Department of Pharmacy faculty on (Vote Pending - 5/18/2020) and is anticipated to be implemented in Autumn quarter 2020. In addition, DOP has aspirations to start a new graduate program in clinical pharmacy. The HEOR title would adequately differentiate the two distinct graduate programs within the same department.

We would like to reiterate that the proposed change in the title of the degree will not require any transition for students in the program. The only change will be that diplomas and transcripts will reflect the new title. Our hope is that all incoming graduate student from 2021 can be offered this degree title. Our current graduate students will be given a choice to select which title they would like on their transcript.

At their faculty meeting on April 27, 2020, the faculty of the CHOICE Institute voted unanimously to approve the new degree title of HEOR. At the faculty meeting of May 18, 2020, the faculty of the Department of Pharmacy voted (Vote Pending - 5/18/2020) to approve this new degree title.

We, the Choice Institute leadership, therefore, submit our proposal and request to change the title of the DOP graduate program in the field of HEOR to bear its correct field name. We are happy to answer any questions you may have in this matter.

Yours truly,

Anirban Basu      David Veenstra

Beth Devine
CURRICULUM VITAE
JOSHUA A. ROTH, PHD, MHA

March, 2020

1. PERSONAL DATA
Place of Birth: Albany, NY, USA

2. EDUCATION
- 2000-2004  BS, Psychology, cum laude, Union College, Schenectady, NY
- 2006-2008  MHA, Health Services Administration, University of Washington, Seattle, WA
- 2008-2012  PhD, Pharmaceutical Outcomes Research, University of Washington, Seattle, WA
- 2014-2015  Graduate Certificate, User-Centered Design, University of Washington, Seattle, WA

3. POSTGRADUATE TRAINING
- 2012-2014  NRSA T32 Post-Doctoral Fellow, Kaiser Permanente of Washington, Seattle, WA
- 2014-2016  K12 Scholar in Patient Centered Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA

4. FACULTY POSITIONS HELD
- 2014-  Associate Member, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
- 2014-  Affiliate Assistant Professor, School of Pharmacy, University of Washington, Seattle, WA
- 2014-2020 Assistant Member, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA

5. HOSPITAL POSITIONS HELD
None

6. HONORS
- 2002-2004  Union College Dean’s List, Union College, Schenectady, NY
- 2004  Alpha Kappa Delta Honor Society, Union College, Schenectady, NY
- 2010  University of Washington Pharmaceutical Outcomes Research & Policy Program Endowed Prize in Health Policy and Economics
- 2010  Best Student Podium Presentation, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting
- 2012  Pre-Doctoral Fellow in Health Outcomes Research, PhRMA Foundation, Washington, DC
- 2013  Best New Investigator Poster Presentation, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting
- 2015  Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research, International Society for Pharmacoeconomics and Outcomes Research
- 2015  Award for Outstanding Paper by a Young Investigator, Society for Medical Decision Making
- 2015  Honorable Mention, Ronald D. Mann Best Paper Prize, International Society for Pharmacoepidemiology
- 2016  Gold-Merit Abstract Award, American College of Radiology Annual Meeting
- 2016  Best Podium Presentation by a New Investigator, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting

7. BOARD CERTIFICATION
Not Applicable

8. LICENSURE
Not Applicable

9. PROFESSIONAL ORGANIZATIONS
- 2008-  International Society for Pharmacoepidemiology
- 2012-  American Society of Clinical Oncology
- 2012-  International Association for the Study of Lung Cancer
10. TEACHING RESPONSIBILITIES

2014-2016 Guest Lecturer, PHARM 536 ‘Advanced Methods in Economic and Outcomes Evaluation in Health and Medicine

2015 Guest Lecturer, PHARM 520 ‘Introduction to Pharmacoeconomics and Outcomes Research’

2015 Workshop Leader, ‘El Valor de la Innovacion en Salud y el Analisis de Impacto Presupuestal’, International Society for Pharmacoeconomics and Outcomes Research Mexico Chapter


A. Fellows and Post-Doctoral Fellows

2014-2016 Ragan Hart MS PhD, MS Thesis (University of Washington)
2015-2018 Sander Brinkhof MSc, Visiting Pre-Doctoral Fellow (Maastricht University, Netherlands)
2016-2018 Jeremey Snider MPH PhD, HICOR-Bayer Post-Doctoral Fellow (Fred Hutchinson)
2016-2017 Anand Singla MD, PHARM 536 Class Project (University of Washington)
2017-2019 Trung Nguyen PhD, HICOR-Bayer Post-Doctoral Fellow (Fred Hutchinson)
2017- Naomi Schwartz MPH, PHARM 536 Class Project (University of Washington)
2018- Yuxian Du PhD, HICOR-Bayer Post-Doctoral Fellow (Fred Hutchinson)
2018- Ashley Kim PharmD, PHARM 536 Class Project (University of Washington)
2019- Jamie Ta PharmD, PHARM 536 Class Project (University of Washington)
2019- Poorni Manohar MD, T32 Research Project (University of Washington)

B. Invited Talks


2015 ‘Health Insurance Coverage as a Potential Barrier to Enrollment in Cancer Clinical Trials: A Prospective, Patient-Level Survey of a Cancer Cooperative Clinical Trials Group’. SWOG Cancer Care Delivery Committee Meeting. SWOG Fall Meeting,
Chicago, IL. September 15, 2016.


11. EDITORIAL RESPONSIBILITIES
None

12. SPECIAL NATIONAL RESPONSIBILITIES

2010- Oncology Outcomes Research Working Group, International Society of Pharmacoeconomic and Outcomes Research

2010- Modeling Good Research Practices Task Force, International Society of Pharmacoeconomic and Outcomes Research


2016-2018 Study Chair, SWOG 1908 ‘Health Insurance Coverage as a Barrier to Enrollment in Cancer Clinical Trials: A Prospective, Patient-Level Survey of a Cancer Cooperative Clinical Trials Group’.

2016-2019 Study Chair, SWOG S1400GEN ‘Ancillary Study to Evaluate Patient and Physician Knowledge, Attitudes, and Preferences Related to Return of Genomic Results in Lung-MAP (SWOG 1400)’.

13. SPECIAL LOCAL RESPONSIBILITIES

2006-2010 University of Washington Institutional Review Board

2009-2010 Admissions Committee, University of Washington Pharmaceutical Outcomes Research and Policy Program

2016-2017 Cancer Prevention Program Head Search Committee, Fred Hutchinson

2016- HICOR-Bayer Post-Doctoral Fellowship Hiring Committee

2018 Cancer Center Support Grant Pilot Study Review Committee
14. RESEARCH FUNDING

A. Current Funding

2015-2020
Sponsor: National Institutes of Health (NHLBI) Development
Title: BMT CTN 1102 Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS Patients
Annual Direct Costs: $267,905
Role: Co-I (PI: SD Ramsey)

2017-2020
Sponsor: Bayer Healthcare
Title: Bayer/Fred Hutchinson 2-Year Post-Doctoral Fellowship in Health Economics and Outcomes Research
Annual Direct Costs: $108,150
Role: Primary Mentor (PI: SD Ramsey)

2018-2020
Sponsor: The American Public Health Association
Title: An Evaluation of the Potential Economic Return of Investments in Cancer Survivorship Interventions in the United States
Annual Direct Costs: $140,965
Role: PI

2019-2020
Sponsor: National Institutes of Health (NHLBI/Emmes)
Title: The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment Option
Annual Direct Costs: $105,704
Role: PI

2019-2020
Sponsor: Fred Hutchinson Cancer Research Center
Title: The Potential Cost-Effectiveness of Treatment with CAR T-Cell Therapy vs. Hematopoietic Stem Cell Transplantation in FHCRC/IIRC
Annual Direct Costs: $140,965
Role: PI

2019-2020
Sponsor: The Anderson Foundation (Fred Hutchinson Pilot Funding Award)
Title: Risk of radiation-induced cardiotoxicity following lumpectomy in early-stage breast cancer
Total Costs: $60,000
Role: PI

2019-2020
Sponsor: Pancreatic Cancer Action Network (PanCAN)
Title: An evaluation of the potential cost-effectiveness of Early Detection Initiative (EDI) screening protocols for the early detection of pancreatic cancer
Annual Direct Costs: $56,818
Role: PI

B. Pending Funding

2019-2024
Sponsor: National Institutes of Health (NHLBI)
Title: Life and Longevity After Cancer (LILAC) Extension
Annual Direct Costs: TBD
Role: Co-I (PI: GA Anderson)

C. Past Funding

2014-2016
Sponsor: Agency for Healthcare Research and Quality
Title: Mentored Career Development Program in Patient-Centered Outcomes Research
Annual Direct Costs: $105,000
Role: K12 Scholar (PI: SD Sullivan)

2015-2017
Sponsor: National Institutes of Health (NCI)—CCSG Pilot Award
Title: Medical Overuse Among Traditionally Underserved Patients: Adherence to ASTRO ‘Choosing Wisely’ Recommendations Among Medicare and Commercially Insured Cancer Patients

Revised 11/13/2018
Annual Direct Costs: $75,000  
Role: PI  
2017-2017  
Sponsor: Genentech  
Title: Health Insurance Coverage as a Barrier to Enrollment in Cancer Clinical Trials: A Prospective, Patient-Level Survey of a Cancer Cooperative Clinical Trials Group  
Annual Direct Costs: $191,796  
Role: PI  
2017-2018  
Sponsor: Safeway Early Career Award in Cancer Research—CCSG Pilot Award  
Title: The Role of Treatment in Racial Disparities in Breast Cancer  
Annual Direct Costs: $79,000  
Role: Co-I (K Reding)  
2012-2019  
Sponsor: National Institutes of Health (NHLBI)  
Title: BMT CTN 1101 Ancillary Cost-Effectiveness Analysis  
Annual Direct Costs: $238,000  
Role: Co-I (PI: SD Ramsey)  
2016-2019  
Sponsor: National Institutes of Health (NCI)  
Title: Ancillary Study to Evaluate Patient and Physician Knowledge, Attitudes, and Preferences Related to Return of Genomic Results in the SWOG 1400 Clinical Trial  
Annual Direct Costs: $56,710  
Role: Study Chair (Parent Trial PI: Blanke)  

15. BIBLIOGRAPHY  

A. Publications in Refereed Journals  


27. Schwartz NRM, Flanagan MR, Babigumira JB, Steuten LM, Roth JA. Cost-Effectiveness Analysis of
Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. American Journal of Managed Care. [In Press] [Original Work]


B. Book Chapters


C. News & Interviews


Revised 11/13/2018


D. Other Publications
None

E. Manuscripts Submitted

F. Abstracts
*Indicates Podium Presentation

2. **Roth JA**, Veenstra DL. “Risk-Benefit Framework to Evaluate Gene Expression Profiling in Early Stage
Breast Cancer: A Decision Model Developed in Collaboration with Stakeholders” at the Society for Medical Decision Making Annual Meeting, Toronto, ON, Canada, October 25, 2010.


12. **Roth JA**, Carlson JJ. “Accounting for uncertainty in the affected population used in value of information analyses: An application in advanced biliary tract cancer” at the Society for Medical Decision Making Annual Meeting, Chicago, IL, October 25, 2011.


33. **Roth JA**. “Improving the Value of PSA Prostate Cancer Screening with ‘Smarter’ Strategies and Increased Use of Active Surveillance”. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 1, 2015.


Accepted Programs and Posters for AACP Annual Meeting 2020

(Competition was fierce this year. Acceptance rates were only 25% and 50%, respectively.)

Platform presentation: “Spark Joy in Precepting: Begin with the end in mind”
Jennifer Chang, University of Washington; Anita Cleven, Pacific University; Huy Hoang, Pacific University

Platform presentation: “But We’ve Always Had Two Midterms and a Final! Rethinking the Student Exam Experience”
Jennifer Bacci, University of Washington; Curtis Jefferson, University of Washington

Platform presentation: “Advancing practice transformation through implementation science”
Jennifer Bacci, University of Washington; Margie Snyder, Purdue University; Carrie Blanchard, University of North Carolina Chapel Hill

Platform presentation: “All for One and One for All: The PPCP Musketeers”
Robin M. Zavod, Midwestern University/Downers Grove; Aleda M. Chen, Cedarville University; Margarita V. DiVall, Northeastern University; Michael J. Gonyeau, Northeastern University; Mary E. Kiersma, Accreditation Council for Pharmacy Education; Jeannine M. Conway, University of Minnesota; Teresa A. O’Sullivan, University of Washington

Platform presentation: “Teaching diagnosis: It’s no longer taboo!”
Mandy Jones, University of Kentucky; Gloria Grice, St. Louis College of Pharmacy; Jeannine M. Conway, University of Minnesota; Jennifer Danielson, University of Washington School of Pharmacy; Karen A. McDonough, University of Washington School of Medicine

Poster: Exploring students’ stress and lived experiences with coordinated block exam scheduling.
Jennifer Bacci, University of Washington; Rachel Allen, University of Washington; Rachel Hansen, University of Washington; Curtis Jefferson, University of Washington